Key factors
sym | LLY |
exch | US |
MCap | 709.22B |
Beta | 0.367 |
PE Ratio | 129.05 |
EPS | 5.78 |
Div | 4.52 |
Div Yld | 0.689 |
Div date | 2024-02-14 |
Yesterday
sym | LLY |
exch | US |
close | 733.51 |
50 Day MA | 762.23 |
200 Day MA | 614.20 |
52 Week High | 800.78 |
52 Week Low | 367.60 |
Target Price | 826.94 |
Market Cap Mln | 709.22K |
Share statistics
Shares Outstanding | 950.76M |
Shares Float | 897.84M |
Percent Institutions | 84.31 |
PercentInsiders | 0.163 |
SharesShort | 5420.67K |
Short Ratio | 1.82 |
Shares Short Prior Month | 5423.38K |
Short Percent | 0.639 |
Income
Revenue TTM | 34.12B |
Revenue Per Share TTM | 37.90 |
Quarterly Revenue Growth YOY | 28.09 |
Gross Profit TTM | 21.91B |
EBITDA | 12.31B |
Diluted Eps TTM | 5.78 |
Quarterly Earnings Growth YOY | 12.99 |
earning
Operating Margin TTM | 0.341 |
PEGRatio | 1.431 |
Trailing PE | 129.05 |
EPS Estimate Current Quarter | 2.22 |
EPS Estimate Current Year | 12.5 |
EPS Estimate Next Quarter | 2.61 |
EPS Estimate Next Year | 18.22 |
Earnings Share | 5.78 |
Dividend
Forward Annual Dividend Rate | 5.2 |
Forward Annual Dividend Yield | 0.689 |
Payout Ratio | 74.21 |
Dividend Date | 2024-03-08 |
Last Split Date | 1997-10-16 |
Last Split Factor | 2:1 |
business
Enterprise Value Ebitda | 86.01 |
Enterprise Value Revenue | 21.59 |
Book Value /share | 11.97 |
Price Book MRQ | 66.34 |
Price Sales TTM | 20.94 |
ProfitMargin | 0.153 |
ReturnOnAssetsTTM | 0.118 |
ReturnOnEquityTTM | 0.484 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Pharmaceuticals |
Gic Sector | Health Care |
Gic Sub Industry | Pharmaceuticals |
Industry | Drug Manufacturers - General |
Sector | Healthcare |
Codes
ISIN | US5324571083 |
CIK | 59478 |
Code | LLY |
CUSIP | 532457108 |
Employer Id Number | 35-0470950 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NYSE |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-04-19 |
Home Category | Domestic Primary |
info
Fiscal Year End | December |
ForwardPE | 60.24 |
Full Time Employees | 43000 |
IPODate | 1978-01-13 |
International Domestic | International Domestic |
MostRecent Quarter | 2023-12-31 |
Contact
Name | Eli Lilly and Company |
Address | Lilly Corporate Center, Indianapolis, IN, United States, 46285 |
Country Name | USA |
Phone | 317 276 2000 |
Web URL | https://www.lilly.com |
Logo URL | /img/logos/US/LLY.png |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.